DOXIL® vs. Xeloda® as First Line Chemotherapy for Metastatic Breast Cancer in Women 60 Years and Older

This study has been terminated.

( The study was terminated due to poor accrual after enrolling 62 of planned 300 patients in 20 months. )

Study NCT00082095 Information provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

First Received: April 29, 2004 Last Updated: April 11, 2008 History of Changes

No Study Results Posted for this Study

Study Status:	This study has been terminated.
Study Completion Date:	December 2005
Estimated Primary Completion Date:	No date given